MARKET

CVKD

CVKD

Cadrenal Therape
NASDAQ
3.290
+0.190
+6.13%
Opening 13:48 06/18 EDT
OPEN
3.260
PREV CLOSE
3.100
HIGH
3.439
LOW
3.170
VOLUME
59.49K
TURNOVER
--
52 WEEK HIGH
14.64
52 WEEK LOW
3.020
MARKET CAP
9.44M
P/E (TTM)
-0.5821
1D
5D
1M
3M
1Y
5Y
1D
Cadrenal Pursues Rare Pediatric Designation for Tecarfarin
TipRanks · 4h ago
Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease
TipRanks · 4h ago
Cadrenal Therapeutics Plans To Submit An FDA Rare Pediatric Disease Designation Request For Tecarfarin As A Treatment For Pediatric Patients With Kawasaki Disease And Coronary Artery Aneurysms Who Need Chronic Oral Anticoagulation
Benzinga · 4h ago
Cadrenal plans FDA rare pediatric disease designation filing for tecarfarin in Kawasaki disease
PUBT · 4h ago
CADRENAL THERAPEUTICS - TO SUBMIT FDA RARE PEDIATRIC DISEASE DESIGNATION REQUEST FOR TECARFARIN IN KAWASAKI DISEASE
Reuters · 4h ago
Analysts Offer Insights on Healthcare Companies: Cadrenal Therapeutics, Inc. (CVKD) and IDEAYA Biosciences (IDYA)
TipRanks · 2d ago
Cadrenal Therapeutics to initiate CAD-1005 trial
TipRanks · 3d ago
Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery
Benzinga · 3d ago
More
About CVKD
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.

Webull offers Cadrenal Therapeutics Inc stock information, including NASDAQ: CVKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVKD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVKD stock methods without spending real money on the virtual paper trading platform.